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To examine the relationship between liver injury and the appearance of bone marrow derived 
hepatic cells we performed sex-mismatched bone marrow transplants in mice, with 
subsequent liver injury.   Co-labeling for a marker of donor bone marrow origin and a marker 
of liver epithelial phenotype allowed us to identify rare marrow-derived hepatocytes at 
various time points following liver damage.  The number of marrow-derived hepatocytes was 
low, however, and did not allow us to determine if liver-specific injury upregulated this 
process from baseline.  We conclude that while marrow-derived hepatocytes are found, the 
low level of occurrence in this study makes it impossible to draw a clear temporal 
relationship between liver damage, recovery and the appearance of donor-derived cells.  In 
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A. Introduction:   
A.1. Liver disease: impact and clinical treatment 
 
Over 26,000 people in the United States die each year from chronic liver disease and 
cirrhosis, making it the twelfth leading cause of death in the US (1).  Cirrhosis is the 
consequence of chronic liver disease and is characterized by replacement of hepatic tissue by 
fibrotic scar tissue and regenerative nodules, leading to progressive loss of liver function.  
Besides the endpoint of death, liver disease and cirrhosis are very costly in terms of human 
suffering, hospital expense, and lost productivity (1).    
At present, the major therapeutic option available for patients suffering from end-
stage liver disease is orthotopic liver allograft.  Shortage of donor organs, subsequent 
requirement for lifelong immunosuppression, and the potential for immunologic rejection in 
the recipient are major limitations of transplantation.  Hepatocyte transplantation, a less 
invasive alternative, is an application hindered by difficulties with obtaining a sufficient 
number of cells for the procedure, problems with the culture and storage of the cells, and 
poor overall engraftment of the cells.  It is clear that alternative therapies are needed.   
A.2. Embryonic stem cells as alternative therapy 
Stem cells have long been of interest in the field of cell therapy and regenerative 
medicine.  There are two major categories: embryonic and adult stem cells.  Embryonic stem 
cells are derived from totipotent cells of the inner cell mass of the human blastocyst, and are 
capable of unlimited in vitro proliferation as undifferentiated cells.  In addition, these cells 
can eventually differentiate down multiple tissue lineages (2, 3).  Better understanding of the 
totipotent capabilities of embryonic stem cells and the elements driving their differentiation 
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to various tissue lineages could lead to dramatic advances in the treatment of various 
diseases.  Because of their early human origins, though, research and use of embryonic stem 
cells has been hotly debated in politics as well as the public.  It is a topic with many legal, 
moral and ethical issues.  In addition, administration of human embryonic stem cells may 
cause tumor formation (4); thus any potential therapies would need to assure that division of 
transplanted cells could be controlled.  
A.3. Adult stem cells as alternative therapy  
The use of adult stem cells for research and treatment is less politically and 
emotionally charged since it does not require the destruction of embryos. Adult stem cells are 
found in many adult tissues including blood, intestine, neurons, skeletal muscle, and skin, 
and support cellular renewal of the tissue to which they belong (5-9).  Traditionally, it was 
thought that only embryonic stem cells could differentiate into adult cells of more than one 
lineage.  Observations calling for adjustments of this view include studies showing that bone 
marrow-derived progenitors participate in regeneration of damaged skeletal muscle (10), 
liver cells (11, 12) , ischemic myocardium (13-15), as well as participate in neurogenesis (16, 
17).  Neural stem cells were shown to participate in hematopoiesis (18), and furthermore, to 
contribute to cells types of all three germ layers (19).  These findings suggest that adult stem 
cells possess the ability to “transdifferentiate”, or differentiate into cell types outside of their 
specific tissue lineage.  This remarkable concept, also termed cellular “plasticity”, calls into 
question not only our traditional views on the role of the adult stem cell, but also the entire 
tri-laminar view of embryonic development.   
Because of their newly discovered pluripotent abilities, including the ability to 
become hepatic cell types, and their relative lack of ethical and legal issues, these cells may 
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be optimal candidates for use in treatment of various liver diseases.  However, the concept of 
plasticity is not free of controversy. Of note, all of the data has not been universally 
confirmed, with some research groups unable to reproduce such findings and other groups 
suggesting mechanisms other than transdifferentiation, such as cell-cell fusion, as the 
responsible phenomena (20-22).  The arguments against plasticity and the concept of fusion 
will be discussed in more detail in section A.11. and A.12, respectively. 
A.4. The bone-marrow and its stem cells 
 
Bone marrow has two components.  The first component is a highly organized 
stromal component that serves as a backbone on which the second component, the cells of 
the hematopoietic system, grow and differentiate.  There are at least two stem cell types in 
the bone marrow: mesenchymal stem cells, which give rise to osteoblasts, chondrocytes and 
other cell types, and hematopoietic stem cells (HSC) which give rise to cells of the 
hematopoietic system (23). 
Functional definitions make it difficult to identify stem cells for research 
 
Plasticity research involving bone-marrow stem cells include experiments using both 
whole bone marrow, as well as specific bone marrow stem cell populations.  Finding a 
reliable way for researchers to identify adult stem cells has been difficult, as these cells are 
traditionally defined by their functional attributes and not by directly observable markers.  
Adult stem cells are defined as a potentially heterogeneous population of undifferentiated 
cells (relative to a functional tissue), capable of proliferation, production of a large number of 
differentiated functional progeny, self-maintenance of their population, regeneration of the 
tissue after injury, and flexibility in use of these characteristics (24, 25).  Functional 
definitions, while the gold standard for reflecting biological roles, create a conundrum in the 
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identification of stem cells.  Identification would require functional testing, including 
differentiation down various lineages.  One would potentially alter the cells original 
properties and render them no longer useful in experimentation (25).  Our current definitions 
based on phenotypic markers, gene expression profiles, and other molecular definitions miss 
essential functional aspects of these cells, but allow researchers to sort and isolate cells. 
Markers for identification of hematopoietic stem cells and their subpopulations  
At present, cell-surface markers are used to identify stem cells.  These markers 
sometimes differ in rodents and humans.  In mice, HSC have been defined by the absence of 
markers of hematopoietic differentiation.  This profile has been termed “lineage negative” 
(Lin-).  In addition, the cell should include low expression of thy-1 (thy-1lo), and high 
expression of c-kit and sca-1 (26).  HSC can be obtained for use either through harvesting of 
bone marrow or by stimulating their mobilization into peripheral blood via granulocyte-
colony stimulating factor (G-CSF) administration and subsequently collecting the blood via 
phlebotomy.  In humans, the major marker for HSC is CD34 antigen (27).  CD34 can not be 
used as a reliable marker in murine studies, however, as the expression of CD34 is rather 
dynamic in the mouse and presence or absence of the marker may not reflect whether the cell 
is a stem cell (28).   For humans, though, it is a very reliable marker, and as a result, the 
presence of CD34 is used to identify the population of cells used in blood stem cell 
transplants in human patients.  Antibodies used to identify CD34+ human cells also reveal 
subpopulations.  AC133 is a monoclonal antibody that identifies the CD133 antigen on some 
cells in what is termed a CD34bright subpopulation.  This subpopulation has been shown to 
have greater hematopoietic reconstituting properties than the CD34dim population in 
xenotransplantation models (29).  In addition to CD34+ populations, CD34- populations have 
5
also been found to have stem cell properties.  In mice, staining HSC with the fluorescent, 
DNA-binding dye Hoechst 33342, identifies a side population (SP) of CD34- cells 
recognized to be a primitive group of stem cells, and is described as CD34-/low, c-Kit+, Sca-
1+ (30).  It was furthermore shown that this SP phenotype was characterized by the 
expression of the ATP-binding cassette (ABC) transporter subtype: ABCG2 (31, 32).  ABC 
transporters have been shown to be upregulated not only in HSCs, but also in oval cells 
(intrahepatic progenitors capable of producing hepatocytes and cholangiocytes) of both 
rodents (33), and humans (34).  This would indicate an overlap of surface markers in 
different tissues, showing that various adult tissue stem cells may be more similar than 
originally thought, and making it more difficult to distinguish between stem cell groups in 
areas, such as the liver, where stem cells from different tissues can mix.   
Hematopoietic stem cells and liver progenitor cells share molecular markers 
 
Interestingly, oval cells, express many factors in common with hematopoietic progenitor 
cells such as: c-kit+, CD34+, Thy-1lo, and Sca-l+ (35, 36).  Moreover, the location that some 
investigators have found oval cells, the periductular/intraportal zone in the liver, also 
suggests that they may originate from an extrahepatic source, possibly bone marrow.  These 
similarities give more credence to the idea that adult tissue stem cells are not lineage-
restricted, and specifically that HSC could become oval cells in the liver.  It has been 
demonstrated that oval cells can arise from bone marrow derived cells (11), discussed further 
in A.6., though other investigators have not been able to reproduce these results (37, 38). 
Markers for mesenchymal stem cells and their subpopulations 
 
Mesenchymal stem cells are known to contain a subpopulation of stem cells known as 
multipotent adult progenitor cells (MAPC).  MAPC have demonstrated a surprising degree of 
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plasticity (39), as have HSC (40) (see section A.6.).  In-vitro, under specific culture 
conditions, MAPC have been shown to differentiate into multiple epithelial cell types 
including hepatocytes (39, 41).  They can be cultured from human, mouse and rat bone 
marrow, and do not express, or express only low levels of, the CD44 antigen (a marker for 
mesenchymal stem cells) (39, 42).  MAPC are CD105 (also called endoglin, or SH2) 
negative (43) and are unlike HSCs in that they do not express CD34 or cKit, but are like 
HSCs in that they express Thy1, AC133 (human MAPC) and Sca1 (mouse), albeit at low 
levels (42, 44).  In the mouse, MAPC express low levels of stage specific embryonic antigen 
(SSEA)-1, and low levels of the transcription factors Oct4 and Rex1.  These are known to be 
important for maintaining embryonic stem cells as undifferentiated and are down-regulated 
when embryonic stem cells undergo somatic cell commitment and differentiation (45).  
Bone marrow may contain stem cells from other tissues 
 
While much work has been done in identifying the various populations of bone 
marrow stem cells, many experiments have been performed with unfractionated bone 
marrow.  Recent studies suggest that the bone marrow compartment harbors adult stem cells 
from other tissues of the body (46), such as liver and muscle.  The stromal-derived factor-1 
(SDF-1)-chemokine receptor 4 (CXCR4) axis, which acts as a powerful chemoattractant for 
HSC, could also have the same chemoattractive effects on early tissue committed stem cells 
(TCSC) not of bone marrow origin.  The authors found a highly mobile population of 
CXCR4+ cells expressing mRNA/proteins for various markers of early TCSC. They 
postulate that the bone marrow is not only a home for HSC, but also a ‘hideout’ for non-
hematopoietic CXCR4+ TCSC (46).  These data underline the need for unambiguous 
markers of various tissue stem cells in plasticity research. 
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A.5. The liver and its regenerative abilities 
 
The adult liver is remarkable in its ability to regenerate after injury.  Mild to moderate 
liver injuries are repaired via rapid proliferation of existing mature hepatocytes.  Experiments 
involving partial hepatectomy (47) or carbon tetrachloride (CCl4) toxicity (48) show that 
liver regeneration can occur by mature hepatocyte proliferation alone.  When liver injury 
either surpasses the regenerative capacity of the hepatocytes or causes hepatocyte 
regenerative capacity to be impaired, liver progenitor cells (oval cells) differentiate into 
hepatocytes and biliary epithelial cells (cholangiocytes) (49-53).  Models of severe injury 
such as CCl4 combined with 2- acetylaminofluorene (2-AAF), a hepatocarcinogen that 
inhibits mature hepatocyte proliferation, show that large numbers of small oval cells appear 
(54).  Subsequent studies showed that these small oval cells were able to differentiate into 
hepatocytes and ductular cells (55), suggesting that these cells indeed are an intrahepatic 
stem cell, and that these cells divide in response to injury overwhelming to mature 
hepatocytes.  Another model of severe injury involves administration of retrorsine, a DNA 
alkylating agent that is selectively taken up and activated by hepatocytes to inhibit their 
proliferation, in addition to CCl4.  The cells responsible for regeneration in this model were 
progenitors expressing phenotypic characteristics of oval cells, but the cells were found to be 
morphologically unique from oval cells (56).  One model for liver regeneration suggests that 
liver regeneration happens on three levels: by way of hepatocytes, intrahepatic stem cells, 
and extrahepatic stem cells (57).  Despite these extraordinary abilities, however, this 
remarkable regenerative capacity can be superseded, as evidenced by various diseases that 
destroy the liver. 
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A.6. Bone marrow stem cells become liver cells 
In light of the new found plasticity of adult stem cells, a number of investigators have 
begun to examine how bone marrow stem cells might be used to rebuild damaged liver. 
Trying to understand the processes controlling the ability of these cells to enter other tissues 
and contribute to various cell types has proved difficult and complex, and is not well 
understood.  
Early studies show bone marrow plasticity in damage models 
 
The first demonstrations of bone marrow-to-liver plasticity employed either sex-
mismatched or strain-mismatched donor and recipient rats.  Male bone marrow was used to 
rescue lethally irradiated female rats, establishing bone marrow chimeras in which marrow-
derived cells could be identified by the presence of the Y chromosome.  Similarly, bone 
marrow from wild-type donors was transplanted into dipeptidyl peptidase (DPPIV)-deficient 
rats, allowing DPPIV to be used as a marker of bone marrow origin.  In each case, liver 
injury was induced after stable engraftment of donor bone marrow cells.    Thus, the bone 
marrow transplant was performed to mark the bone marrow, and was not intended to have 
any therapeutic impact on the liver.  2-AAF was administered to intentionally suppress 
regeneration from mature, native hepatocytes.  In addition, CCl4 was given to produce acute 
hepatic injury and regeneration including oval cell upregulation.  After liver injury, Y 
chromosome positive (male) hepatocytes were found in female animals, and in DPPIV 
deficient rats, DPPIV positive hepatocytes and oval cells were found (11).  This showed that 
marrow-derived stem cells could act as hepatic cell progenitors in a model of impairment of 
the hosts own regenerative capabilities. 
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Bone marrow plasticity in models lacking injury 
 
The potential plasticity of HSC, rather than whole marrow, was evaluated by 
transplanting single, male, lineage-, HSC into irradiated female recipients (along with 
supporting female donor cells).  In addition to complete bone-marrow reconstitution, male 
hepatocytes and cholangiocytes, and male epithelial cells throughout the gastrointestinal 
tract, bronchus, and skin were found by colocalization of fluorescence in situ hybridization 
(FISH) for Y chromosome and immunohistochemistry (IHC) for various epithelial markers 
(40).  
Additional studies demonstrated marrow-derived hepatocytes in the absence of liver 
damage.  Male bone marrow was infused into lethally irradiated female mice and allowed to 
stably engraft for 6 weeks.  Detection of donor and host-specific phenotypes was performed 
by FISH for Y chromosome, and albumin mRNA detection for hepatocytes.  A significant 
number of donor-derived (Y chromosome positive) hepatocytes were found by co-
localization of the two labeling techniques (12).  
A.7. Injury vs. non-injury models of plasticity 
 
In multi-organ engraftment studies, the highest levels of donor-derived cells, as well 
as the most diffuse clustering of donor-derived cells, were seen in alveolar epithelium (39).  
It had been postulated that the higher level of engraftment in this tissue is likely related to the 
fact that lung tissue is known to be more radiosensitive than other tissue (58).   Therefore the 
increased injury induced by irradiation may have been responsible for the increased levels of 
engraftment.  The relevance of liver irradiation to transdifferentiation in hepatic models is 
less clear because while liver damage via irradiation is known to occur (59), it tends to be 
seen at larger doses than that delivered during bone-marrow ablation (1000-1200 rads).  
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Neither of the two studies showed evidence of tissue damage, histologically, leading 
researchers to consider the possibility that marrow-derived hepatocytes may occur in 
minimal liver injury, or even in physiological maintenance.   At appropriate doses, liver 
irradiation can decrease the hepatocyte’s own ability for regeneration (60), and therefore may 
be a useful model for studying injury and its effects on marrow-derived engraftment in the 
liver. 
Injury increases engraftment of hepatocytes by bone marrow 
 
Regardless of injury method, studies with moderate to severe liver damage tend to 
show increased hepatic engraftment of marrow cells. One study employed an in vivo 
selection strategy, based on the protective effect of Bcl-2 against Fas-mediated cell death, to 
confer a survival advantage to the progeny of transplanted bone marrow cells.  Donor 
marrow was harvested from mice over-expressing the Bcl-2 gene under the control of a liver-
specific promoter and transplanted into normal mice.  The mice were then injected repeatedly 
with Fas-agonist antibody to induce severe apoptotic liver injury, while the control group did 
not receive Fas-agonist antibody.  After multiple cycles of apoptotic injury and recovery, 
mice that received the Fas-agonist antibody developed clusters of mature marrow-derived 
hepatocytes expressing Bcl-2 (61).  This study helped to show that while transdifferentiation 
under physiological conditions may be an insignificant event, liver injury and in vivo 
selection may upregulate this process.   
In a model of CCl4-induced liver fibrosis,  GFP+ bone marrow cells from donor mice 
contributed to approximately 26% of the recipient liver 4 weeks post transplant (62).  
However, the extraordinarily high percentage of engrafting cells has been criticized for 
ambiguous identification methods and unusual architecture of the GFP-expressing cells (63).  
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Damage seems to increase engraftment, but not in predictable ways 
Presence and severity of liver injury are likely important in stem cell plasticity and 
engraftment, yet there is large variation in the reported extent of plasticity via severe liver 
damage models.  Estimates of the percentage of marrow-derived cells range from zero 
percent (64), to nearly 30% hepatic repopulation at 4 weeks post transplant (62).  One 
possibility for these observed differences may lay in the ability of different subpopulations of 
adult stem cells to differentiate into functional tissues.  This cause of divergence likely plays 
a role in not only damage studies, but non-damage studies as well, and suggests a need for 
researchers to define groups of marrow stem cells before their experimental use.  This and 
other possible reasons for variations in different results are discussed in section A.11. 
A.8. Do Adult Tissue Stem Cell-Derived Hepatocytes Have Functional Significance? 
 
The studies above suggest that marrow-derived stem cells can contribute to hepatic 
regeneration, yet the ability to apply this phenomenon in medicine would depend on whether 
these engrafted cells have sufficient function.  Testing for function in marrow-derived 
hepatic cell types has proven difficult.  Studies with the most success use models where 
recipient animals are mutant, lacking normal cell function in the tissue being studied, and 
donor animals are wild type for this characteristic.  In this way, donor cells restore function 
to recipients.  Functional analysis was carried out in experiments with fumarylacetoacetate 
hydrolase (FAH) deficient mice.   This is a model of fatal hereditary tyrosinemia liver 
disease.   Wild-type bone-marrow was transplanted into lethally irradiated FAH- mice.  FAH- 
mice will develop progressive liver failure unless treated with 2-(2-nitro-4-trifluoro-
methylbenzoyl)-1,3-cyclohexanedione (NTBC) to prevent accumulation of toxic catabolites 
of tyrosine.  Post bone marrow transplantation, NTBC feedings were cyclically halted, 
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creating liver damage and therefore selecting for liver-repopulating conditions.   After 
euthanasia, up to 30-50% of liver mass was bone-marrow derived.  In addition, large donor-
derived nodules consisting of morphologically normal, FAH+ hepatocytes were visualized.  
Biochemical functional assessment of the marrow-derived cells revealed expression of liver 
hydrolase (previously missing in the FAH- recipients) to nearly normal levels.  This led to 
long-term survival of the animals without a need for NTBC feedings (65).  Therefore in 
rodents, it appears that HSC have the ability to contribute to functional liver repair in a model 
of liver injury where there is a survival advantage of the infused stem cells.  Subsequent 
analysis of marrow-derived hepatocytes in this model suggested that some, if not all, of the 
resulting functional hepatocytes may be a result of fusion between diseased native 
hepatocytes and donor-derived cells of the monocyte-macrophage lineage.  The role of fusion 
will be discussed in detail in part A.12. 
A.9. Plasticity of bone marrow cells has also been found in humans   
 
The establishment of a role for bone marrow stem cells in engraftment and repair in various 
tissues other than bone marrow in mouse studies has been an important first step in 
understanding how to better use the capabilities of these cells in human disease.  Therapeutic 
clinical use of such technology, however, would only be possible if there is evidence that 
human adult stem cells also have the plastic capabilities seen in adult rodent stem cells.  The 
first reports that hinted at transdifferentiation in human cells occurred with archival biopsies.  
Liver specimens from recipients of sex-mismatched bone marrow or liver transplants were 
analyzed to look for marrow-derived hepatic cells.  FISH for the Y chromosome as well as 
IHC for markers in liver cells was employed to analyze liver and bone marrow samples.  Y-
positive hepatocytes were found in female patients who had received male bone marrow 
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transplants and y-positive hepatocytes were also found in female livers that had been 
transplanted into male recipients (66), suggesting the engraftment of a circulating progenitor 
in the liver of the recipient.  Marrow-derived hepatocytes and epithelial cells of the skin and 
gastrointestinal tract were seen in patients who had first received myeloablative therapy, and 
then received an infusion of peripheral-blood stem cells for the treatment of hematological 
malignancy (67).  This showed that marrow-derived progenitors circulate in the blood and 
contribute to non-hematopoietic tissues in humans.   
One concern that arose from these studies was that perhaps the Y chromosome 
positive hepatocytes were not the result of transdifferentiation, but instead a result of 
transplacental passage of male fetal progenitor cells during pregnancy (68).  Fetal-maternal 
microchimerism has been documented (69, 70), but can not be completely responsible for y-
positive hepatocytes in the previous studies.  Marrow-derived cells have been seen after bone 
marrow transplantation in human liver from nulliparous females (66, 68) and in a female 
with no history of male child-bearing (71).  In murine models, female recipients were 
nulliparous (12). 
Increasing injury correlates with increasing engraftment in archival biopsy studies 
 
 Further analysis of human archival biopsy tissue showed that increasing severity of 
liver injury correlates directly with hepatic engraftment frequency.  Human liver allograft 
biopsies revealed varying degrees of liver injury ranging from mild biliary obstruction in 
most to fibrosing, cholestatic hepatitis in one.  Hepatic engraftment frequency was seen to 
increase with increasing liver injury (66).  Contrary to this, recipients of bone marrow 
transplantation who did not have hepatic injury demonstrated hepatic engraftment despite the 
lack of liver injury (66), in keeping with the results found also in murine studies (12).  This 
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suggests, as in the animal data, that there is a role for adult tissue stem cell engraftment both 
in physiological maintenance as well as in acute injury. 
In-vivo evidence of plasticity and functionality of derived cells with human adult stem cells 
 
 While archival biopsies have revealed much information, it is clear that better models 
for studying human cells in-vivo are needed.  One report studied in-vivo physiological 
maintenance roles of tissue stem cells.  Human cord blood cells were injected into sublethally 
irradiated nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, and 
human-derived hepatocytes were found in murine liver (72).  In a similar study, these human-
derived hepatocytes were found to produce human albumin mRNA, detected by reverse 
transcription-polymerase chain reaction (73).  
To study in-vivo engraftment of human cord blood cells in a model of hepatic injury, 
hepatic injury was induced via one-third partial hepatectomy and 2-AAF in mice.  Functional 
human-derived hepatocytes were found (74).  Comparison between a group of mice with 
CCl4 induced liver injury and a non-injured groups of mice showed that only mice who had 
been administered CCl4 in addition to receiving a CD34+ fraction of blood were found to 
express human albumin (75). 
A.10. Homing mechanisms of bone marrow stem cells to liver:  SDF-1/CXCR4 axis and 
hepatocyte growth factor help bone marrow migrate to liver and become hepatocytes 
 
 Study of the stromal-derived factor-1 (SDF-1)/CXC chemokine receptor 4 (CXCR4) 
axis has given insight on how HSC migrate to damaged liver.  The SDF-1/CXCR4 axis was 
shown to regulate movement of HSC toward damaged liver in a NOD/SCID model (76).  In 
addition, hepatocyte growth factor, a substance that is upregulated in liver injury (77) and has 
been shown to help HSCs differentiate into hepatic cells (75), was shown to be a key player 
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in the recruitment of stem cells.  This was found to occur through hepatocyte growth factor’s 
interactions with SDF-1 (76).   
A.11. Plasticity is not supported universally in the literature 
 
While the concept of plasticity is one that conjures excitement and hope for the field 
of regenerative medicine, it has been questioned by some groups who have been unable to 
reproduce similar findings.  No evidence of epithelial engraftment at physiological conditions 
was seen in parabiotic mice, in which two mice, one GFP+ and the other GFP-, shared a 
common circulation.  Under these conditions, with no specific injury, cross-engraftment of 
hematopoietic tissue was found, but no engraftment of non-hematopoietic tissues was 
discovered (20).  In another model, no significant hepatic engraftment was found after sex-
mismatched bone marrow transplant (78).   
Reasons for variation in findings among studies 
The negative results of these experiments may be attributed, at least in part, to model 
systems chosen.  For example, GFP may exhibit weak and variable expression in epithelial 
cells of the donor animal.  Other reasons for the variations in results may be age of donor 
mice, length of time after transplantation that tissues are examined, purification techniques 
during isolation of stem cells, and methods used for detection of donor-derived cells. These 
reasons are explored in detail in a recent commentary (79).  The population or subpopulation 
of stem cells used in experiments may also play a role.  While initial studies used 
unfractionated bone marrow, newer work showed the capacity of CD34+ cells, specifically, 
for hepatic engraftment (12).  The SP fraction of bone-marrow cells, discussed earlier as a 
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CD34- primitive population (28, 30), was also demonstrated  to contain cells with ability for 
hepatic engraftment (80). 
A.12. Fusion could to play a role in observed plasticity  
 
Other work has challenged the concept of plasticity by suggesting that some or all putative 
transdifferentiation events are instead the result of cell-cell fusion (between donor-derived 
blood cells and existing differentiated cells).  An in vivo study infused wild-type male 
marrow cells into female FAH- mice.  FAH expressing liver nodules were found, and 
genomic analysis of the DNA dissected from the liver nodules was performed.  The DNA 
was probed for FAH sequences and Y chromosome sequences to measure the proportion of 
donor alleles.  Hepatic nodules contained more mutant than wild-type FAH alleles, and nodal 
hepatocytes expressed both donor and host genes.  The authors found this to be most 
consistent with polyploid genome formation by fusion of host and donor cells (81).  Another 
study, also using wild type male donor marrow into FAH- female mice, performed serial 
transplantation of bone marrow.  Genomic DNA from bone marrow derived hepatocytes 
from the tertiary recipients was analyzed.  While massive liver repopulation had occurred, 
only a very small amount of the original donor genotype was preserved in the cells, far less 
than expected if the cells had come solely from transdifferentiation of HSCs (65).  Another 
group employed karyotype analysis to address the fusion issue.  Wild type bone marrow from 
female mice was injected into male FAH- mutants, and chromosomes from the metaphase 
part of the cell cycle were analyzed.  Control nuclei and up to half of the derived hepatocytes 
had the expected normal male diploid (56, XY) or tetraploid (81,XXYY) karyotype.  Most of 
the rest of the cells had karyotypes consistent with donor-recipient fusion.  In addition, only a 
small amount of cells contained only X chromosomes, revealing that the original donor 
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female karyotype had been lost, also consistent with fusion (80).   Other investigators created 
models based on the normal ploidy values for murine hepatocytes that predicted the 
percentage of donor DNA that should be present in regenerated nodules if fusion had 
occurred and if it did not occur.   Each of the nodules analyzed yielded values outside the 
predicted range for transdifferentiation alone (81).    
It is known, however, that conditions of liver injury and impairment of DNA repair 
mechanisms (such as via ionizing radiation) can cause advanced hepatic polyploidy as well 
as terminal differentiation and cell senescence (82, 83).   Some suggest that hepatic 
polyploidy may come from fusion of multinuclear cells and may account for some of these 
results.  Besides liver, there have been reports of fusion of bone marrow cells with cardiac 
myocytes and purkinje neurons in vivo (22).    
If fusion accounts for the observed events, it is necessary to determine which cells are 
fusing with host liver cells.  It could be the donor HSC, but it has also been suggested to be 
hematopoietic progeny from the HSC, including macrophages, also known as Kupffer cells 
in the liver (81).  Macrophages are likely candidates due to their large number, location, and 
because they tend to fuse with cells under other conditions (84).  In fact, it has been 
suggested that cell plasticity can be explained by donor HSC homing to the bone marrow and 
creating myeloid cells that then can fuse with recipient tissue cells (85).  Liver injury could 
call upon the circulating myeloid cells, descended from donor HSC, as part of an 
inflammatory response to injury.  Inflammation may create a fusogenic environment by 
facilitating myeloid cell recruitment to liver (or other tissue) where subsequent fusion with 
the parenchyma can occur.  Experimentally this scenario has been demonstrated by 
transfusing lymphocyte-deficient cells, then mapping the fate of the myeloid lineage.  HSC-
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derived hepatocytes were found to derive primarily from myeloid cells, indicating that they 
are the cells responsible for fusion (86).  
Some models of plasticity are not consistent with fusion 
 
Other studies show that fusion does not account for bone marrow plasticity.  In xenogeneic 
studies where human cells are transfused into rodent recipients, FISH analysis of human and 
murine DNA as well as nuclear staining patterns showed no evidence of fusion between cells 
(72, 73).  Researchers transplanted lethally irradiated female mice that ubiquitously 
expressed Cre recombinase with bone marrow from male Z/EG Cre-reporter donor mice.  In 
this model, cells resulting from fusion of a bone marrow derived cell with a host cell should 
express enhanced green fluorescent protein (EGFP), and would therefore be distinguishable.  
When analysis of tissues was performed, Y chromosome positive, recipient epithelial cells 
were noted without EGFP expression.  Therefore no fusion was observed in bone-marrow 
derived epithelial cells(87). 
A novel in-vitro model system aimed at discriminating between fusion and 
transdifferentiation involved the co-culturing of murine HSC with either normal or damaged 
liver tissue.  The HSC and liver cells were separated by a trans-well membrane.  In this 
system, the cells would not be allowed to fuse since there was no contact between the HSC 
and liver cells.  Immunofluorescence showed that the HSC co-cultured with damaged liver 
lost their hematopoietic phenotypes as they began to express albumin.  Tissue-specific 
markers normally expressed during liver differentiation were also detected providing further 
evidence of the HSC to hepatocyte conversion.  Cytogenetic analysis of the cells gave further 
assurance.  The model system was such that the HSC were male cells and the liver tissue was 
from female donors.  Analysis revealed tetraploid cells amongst the HSC, though the 
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karyotype was XYXY and therefore only derived from male cells, HSCs with other HSC, 
and not from HSC fusion with female liver cell (XXXY).  The investigators concluded that 
there is genuine plasticity of HSC cells and that HSC transdifferentiation is an early event (in 
contrast to the studies above) with microenvironmental cues responsible for the germ-layer 
switch (88).  
FAH model systems, fusogenic environments and normal hepatocyte polyploidy could 
account for both real and apparent fusion outcomes 
 
In addition to the above evidence against fusion as the sole mechanism for apparent 
plasticity, there are issues that have been found with the FAH-null model (a key model 
responsible for suggesting fusion as a cause for donor derived hepatocytes).  It has been 
suggested that since in the FAH-null model there is extreme architectural disruption and 
membrane instability of hepatocytes, this environment may lend itself more to fusion (89).  
In addition, hepatocytes are known to fuse in pathological conditions.   
Important to note is that hepatocytes can also be multinucleate and polyploid under 
normal conditions.  Hepatocytes are tolerant of high ploidy without any evidence of 
malignant transformation.  This should be considered when DNA and karyotype analysis is 
employed to determine if fusion has taken place.  
Fusion and plasticity may occur together  
Reports supporting stem cell plasticity (87, 90, 91), as well as convincing in-vitro 
HSC plasticity accounts (86) make it difficult to attribute plasticity to fusion alone.  While 
fusion may well be occurring, it seems unlikely that it is the sole mechanism for engraftment.  
Investigators reporting multipotent adult cells derived from adult human bone marrow (39) 
that were able to differentiate in vitro into a number of mature cell types including functional 
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hepatocyte-like cells (41), suggest true adult cell plasticity, at least in vitro.  Cell fusion may 
occur in some systems, while transdifferentiation with or without fusion may occur in others.  
At present, the factors regulating this are unclear and need to be better understood before 
these phenomena, both plasticity and fusion, can be of clinical use.
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B. Hypotheses and Study Aims: 
 
The liver is extraordinary in its ability for intrahepatic cells to proliferate and 
differentiate in response to liver damage.  Hepatocytes and liver progenitor cells, oval cells, 
can both contribute to regeneration depending on types and severity of injury.  It has recently 
been found, however, that human as well as mouse blood and bone marrow can also give rise 
to hepatic cell types (40, 66, 67, 75).  The mechanisms by which this seemingly plastic event 
takes place are still to be determined.  Learning more about the process by which these blood 
and marrow cells are able to contribute to hepatic cell types, and facilitating the 
transformation to a high enough level could enable us to better utilize this phenomena in the 
cellular therapy of various liver diseases.  Reports on the plasticity of blood and bone marrow 
cells indicate that the process may be one occurring physiologically or may be upregulated 
by liver damage and can occur without fusion (73, 87, 88).  These reports suggest a degree of 




B.1. Hypothesis:  Oval cells can arise from bone marrow and can engraft the liver as 
epithelial cells.  Furthermore, since oval cells are presumed to be the stem cells for the liver, 
engraftment of marrow derived cells into oval cells will ultimately lead to marrow-derived 
hepatocyte and cholangiocyte progeny of the engrafted oval cell. 
B.2. Aims of the Study:   
 
Aim 1:  Induce oval cell proliferation in male/female bone marrow chimeras using 
DDC. 
 
By feeding 3,5 diethoxycarbonyl-1,4 dihydrocollidine (DDC), a toxin known to cause 
cholestatic liver injury and to increase oval cell proliferation, to male into female bone 
marrow chimeric mice we hope to induce severe, but reversible, injury to the liver with 
upregulation of oval cell proliferation.  We hope to determine if the DDC-damage induced 
hepatocytes and cholangiocytes are, at least in part, marrow-derived.  In addition, by using 
the DDC damage model we hope to be able to learn more about the temporal relationship of 
the appearance of marrow-derived hepatocytes to liver damage and recovery 
Aim 2: Inhibit hepatocyte proliferation by focal irradiation of the liver. 
 
 By treating mice with liver-specific irradiation, we hope to further suppress the regenerative 
capabilities of the cells within the liver so that we may enhance the homing and engrafting of 
marrow-derived cell types into hepatic cell types.  We will compare this to a group of mice 
not treated with liver-specific irradiation to learn more about types of damage and their 
effects on marrow-derived cell engraftment in the liver. 
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C. Materials and Methods: 
 
C.1. Stem cell isolation and transplantation 
To isolate bone marrow cells, 6 week old, male, C57Bl6 mice (Jackson Laboratories, Bar 
Harbor, ME) were anesthetized with isoflurane (Abbott Labs, Chicago IL), sacrificed by 
cervical dislocation and hind limbs were removed.  Bone marrow was flushed with a 25 
gauge needle in sterile fashion from the medullary cavity of the tibias and femurs with 
medium containing IMDM + 5% FCS.  This technique has an approximate yield of 10 x 106 
cells per mouse.  1.0 x 106 male mononuclear bone marrow cells were injected into the tail 
veins of 20 female C57Bl6 mice previously treated with a lethal dose (1100rads) of whole 
body irradiation in a cesium irradiator.  Transplanted marrow was allowed to engraft for 6 
weeks. 
C.2. Liver Irradiation and DDC exposure 
12 of the female bone marrow transplanted mice received focal irradiation (Siemens 
stabilipan x-ray source) of 1000 rads, limited by lead, to the upper abdomen to inhibit 
hepatocyte regeneration from existing hepatocytes. All mice (those treated with focal 
irradiation as well as those who were not) were then fed for 10 days with a 0.1% DDC 
(Research Diets Inc) diet to stimulate oval cell proliferation. Mice were sacrificed by 
isoflurane at 0, 7, 14, 21, 42, 63, and 84 days following the last dose of DDC.  
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C.3. Tissue Processing 
Portions of liver and spleen were collected, fixed in phosphate buffered formalin at room 
temperature for 4 hours, and then embedded in paraffin.  Three micron sections were cut for 
further analysis. 
 
C.5. Immunohistochemistry and FISH Analysis  
Slides were deparaffinized via heating and Citrisolv treatment, and rehydrated through 
graded alcohols to phosphate buffered saline (PBS).  Antigen retrieval (a method of 
recovering the antigenicity of tissue sections that has been masked by formalin fixation) was 
carried out with Retrieval-All-2-pH10 (Signet Labs, Dedham, MA) for 30 min in a steamer.  
Slides were then cooled, washed in PBS, then water, and air-dried.  A digoxigenin-labeled 
mouse Y chromosome probe (Prepared as in Krause et al., Cell Vol. 105, 369-377, 2001) was 
applied.  Coverslips were sealed with rubber cement and DNA was denatured at 600C for 6 
minutes.  Following an overnight hybridization at 370C, slides were washed in 0.2X SSC for 
3 minutes at 420C.  Non-specific protein binding was blocked with 2XSSC, 3%BSA, 
0.1%NP40 for 30 minutes.  Detection of the Y chromosome was performed by adding anti-
digoxigenin rhodamine (Roche)(1:10), in 4XSSC, 1%BSA, and 0.1% T20 for 1 hour at 370C.  
Slides were washed in PBS, and a 1:25 dilution in PBS-1% bovine serum albumin (BSA) of 
rabbit anti-human polyclonal antibody to hepatocyte nuclear factor (HNF-1) (Santa Cruz 
Biotechnology) was applied overnight at 40C.  Following PBS washes, the secondary 
antibody, goat anti-rabbit FITC (Invitrogen)(1:50 in PBS/1%BSA), was incubated on the 
slides for 1 hour at 370C. Slides were washed in PBS, air-dried, and mounted in vectashield 
fluorescence mounting media with DAPI (Vector Labs, Burlingame, CA). 
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C.6. Tissue analysis and Cell Counts 
Counting of y-positive, HNF-1-positive hepatocytes was accomplished by systematically 
examining the treated slides, field by field, under 40x magnification, using an Olympus BX-
51 microscope.  Y-FISH and HNF-1 double positive cells are identified using a dual-
wavelength channel filter set designed for simultaneous visualization of FITC and 
Rhodamine (Chroma Technology).  Photomicrographs were taken using a digital camera and 
IPLab imaging software (BD Biosciences, Rockville, MD).  Separate images were obtained 
using filters for DAPI (all nuclei), rhodamine (Y chromosome), and FITC (HNF-1), then 
merged.  Cell counts were derived from these images.  Hepatocytes were identified by HNF-
1 nuclear staining, and also histologically as large polygonal cells, arranged in plates, with 
large, round nuclei.  Select hepatocytes, with both HNF-1 and Y chromosome labeling, were 
further analyzed by confocal microscopy (Zeiss LSM 510 microscope).  Hematoxylin and 
eosin stained sections of each sample were also prepared, and light microscopic photographs 
were taken on the Olympus BX-51 microscope in order to examine the histology of the liver 
samples and various liver damage. 
C.7. Statement of animal care 
This research proposes the use of liver injury and bone marrow transplant models to 
determine the mechanism of liver engraftment by bone marrow stem cells.  The liver injury 
models have been approved by the Yale Institutional Animal Care and Use Committee 
(IACUC) (2004-10416, 3/3/2004).  Bone marrow transplantation is also approved under this 
protocol.  Animals were cared for in a humane manner in accordance with IACUC standards. 
26
C.8. Statement on persons completing various portions of labor 
Bone marrow isolation and transplantation, liver irradiation and DDC exposure, animal 
sacrifice, tissue processing, immunofluorescence and FISH analysis, were all performed by 
this author as well as Scott Swenson.  Tissue analysis and cell counts were in the vast 
majority performed by Scott Swenson, with minor analysis contributed by this author.  
Confocal microscopy was done by Scott Swenson.  Labeling of paraffin tissue sections with 
hematoxylin and eosin was done by the Yale Research Histology Lab.  Images from 
hematoxylin and eosin stained sections were gathered by this author.  The thesis was written 
by this author. 
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D. Results: 
D.1. Experimental design   
To determine whether bone marrow cells differentiate into liver progenitor/oval cells, 
lethally irradiated female mice were reconstituted with bone marrow from male donors.  This 
transplantation served to mark the cells of marrow origin. The donor marrow was allowed to 
stably engraft for six weeks.  Reconstitution using this protocol typically replaces >80% of 
the recipient bone marrow with donor marrow.  Subsequently, the mice were treated with 
DDC diet for 10 days in order to cause acute liver injury and stimulate the activation and 
proliferation of oval cells.  A subset of the bone marrow chimeric mice were also subjected 
to liver-specific irradiation on day 0 of the DDC diet for the purpose of suppressing 
hepatocyte proliferation after injury and favoring mobilization of potential progenitor cells 
from outside the liver.  The experiment design is summarized in Figure 1.a.  The apparatus 
for liver irradiation is shown in Figure 1.b.  Control mice received no post-transplant injury.  
Mice were sacrificed at 0, 1, 2, 3, 6, 9, and 12 weeks after completing a 10-day course of 
DDC diet, with or without liver irradiation.  These points were selected in order to monitor 
the appearance of marrow-derived hepatic cells over time.   
D.2. Histological changes 
Paraffin sections of control and experimental animals were stained with hematoxylin 
and eosin in order to observe histological changes induced by DDC alone, or DDC plus liver 
specific irradiation, as well as to observe histological recovery from these injuries over a 
period 0-12 weeks post completion of the 10 day DDC diet (Figure 2).  Normal murine liver 
is shown in Fig. 2a.  Fig. 2b shows liver from a control (bone marrow transplant without liver 
injury) mouse.  Both the normal and control liver sections show no apparent abnormalities.  
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In both groups, histological changes were seen at 0, 1, 2, 3, 6, 9, and 12 weeks (Figure 2c-e) 
after completion of the DDC diet.  Ductal proliferation, inflammation involving both oval 
cells and inflammatory cells, and cholestasis can be seen in both experimental groups at all 
time points of recovery.  Histologic recovery from DDC injury was delayed by liver 
irradiation. 
D.3. Biochemical injury 
Blood samples were taken from experimental mice at 0,1,2,3,9 weeks post 
DDC/DDC and liver specific irradiation injury, to analyze for biochemical injury and 
recovery, and to better understand which parts of the liver have been affected by the inflicted 
damage.  Elevation of alanine aminotransferase (ALT) above normal levels (50 - 160 units/L) 
is a measure of hepatic cell inflammation, while elevation of alkaline phosphatase above 
normal levels (1 - 21 units/L) indicates inflammation of the biliary tract cells, cholangiocytes.  
The DDC-induced biochemical injury, shown in Figure 3, was reversible in both the 
irradiated and non-irradiated group, and did not appear to be worsened by hepatic irradiation 
with 1000 rads.  Both ALT and AP show large elevations from the normal range, peaking at 
the end of the DDC treatment period (0 weeks recovery) and subsequently declining toward 
normal.  
D.4. Y chromosome positive cells in the liver of recipient animals 
The identification of marrow-derived hepatic cells requires the simultaneous 
detection of markers for both donor and recipient cell phenotypes.  The Y chromosome is a 
useful marker of donor origin because it is unique to our donor animals and is readily 
detected in the nucleus by FISH.   Hepatocyte Nuclear Factor-1 (HNF-1), a transcription 
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factor highly expressed in the nucleus of hepatocytes, cholangiocytes and oval cells, is a 
useful marker of recipient origin because it is not expressed in any cells of blood lineage, and 
can be easily detected by immunofluorescence.  In addition, HNF-1 is also expressed in 
epithelial cells of the intestine, pancreas and kidney. Within the liver, HNF-1 is not expressed 
in endothelium, stellate cells, or fibroblasts.   
By employing a double label FISH/immunofluorescence protocol, we were able to 
detect both Y chromosome and HNF-1 in formalin-fixed, paraffin embedded tissues of the 
liver.  To be considered a marrow-derived hepatocyte or cholangiocyte, a given cell was 
required to have both Y chromosome and HNF-1 unambiguously in its nucleus.  Having both 
markers in the nucleus of the target cell ensures less chance of mistaking a marrow derived 
hepatic cell for a marrow-derived blood cell closely adjacent to a non-marrow-derived 
hepatic cell.  Fig 4a shows normal male murine liver co-labeled for Y chromosome (pink) 
and HNF-1 (green).  Nuclear DNA is stained blue by DAPI dye.  Autofluorescence of 
hepatocyte cytoplasm and red blood cells is greenish-yellow, and yellow, respectively.  
Nearly all cells contain at least one Y chromosome whereas only hepatocytes and 
cholangiocytes express HNF-1.  Figure 4b shows normal female liver.  There was no Y 
chromosome detected in any of the cells, indicating that false positive detection of Y 
chromosome in transplant recipients was very unlikely.  Nuclear labeling of HNF-1 is 
identical to that of the male liver, as expected.  Figure 4c and d shows a marrow-derived 
hepatocyte in the liver of a mouse from the experimental group receiving no liver-specific 
irradiation.  This photograph was taken from an animal sacrificed 1 week after withdrawal of 
the DDC diet.  Figure 4d is an enlargement of 4c.  Note the cytoplasm of the hepatocyte can 
be seen completely encircling the nucleus, and that the Y chromosome and HNF-1 labeling 
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are confined to the nucleus.  For further assurance that this was not merely a blood cell 
overlying, or very closely adjacent to, a hepatocyte, the slide was then imaged by confocal 
microscopy (Figure 5).  The co-labeling of Y and HNF-1 are confirmed to be contained 
within the same nucleus, rather than an artifact of proximity or overlap. 
Double-labeled hepatocytes, such as the one in Figure 4, were sought, field by field, 
in tissue sections from each of our mice.  In preliminary counts, out of approximately 37,500 
hepatocytes counted from mice in the experimental groups, 4 marrow-derived hepatocytes 
were found at 1, 9, and 12 weeks after DDC treatment.  3 of the 4 hepatocytes found were 
from the experimental group not receiving liver-specific irradiation.  From 5,100 hepatocytes 
counted from mice in the control group, 1 marrow-derived hepatocyte was observed.  
Marrow-derived cholangiocytes or oval cells were not found.  These results are summarized 
in Table 1. 
The rarity of the marrow-derived hepatocytes limited our ability to draw a temporal 
relation between recovery from toxic injury and the appearance of these cells.  We were also 
unable to determine whether or not the toxic damage from DDC, with or without irradiation, 
caused an increase in the number of marrow-derived hepatocytes from baseline because so 
few were found.  
In attempting to count marrow derived hepatocytes it became apparent that there were 
potential pitfalls to this process.  First, as the injury model had induced an inflammatory 
response, there were a large number of inflammatory cells in the liver tissue.  These cells 
were in very close contact with many of the hepatocytes, and it could be difficult to 
determine whether a nucleus containing a Y chromosome was from a blood cell or a 
hepatocyte.  In some cases, confocal microscopy would be necessary.  Figure 6 is highly 
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suggestive of fusion between a male marrow-derived (likely inflammatory) cell and a female 
recipient hepatocyte.  Here the hepatocyte appears binucleate, as normal hepatocytes may be. 
However, HNF-1 staining is absent from the y-labeled nucleus, and the HNF-1-positive 
nucleus is Y chromosome-negative. These images clearly demonstrate the critical importance 
of using a nuclear marker of hepatocyte phenotype in these experiments. 
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E. Discussion:   
Our studies did not show that bone marrow cells could become oval cells.  Since the 
source of oval cells in the liver has not yet been determined unambiguously, and since bone 
marrow stem cells have been shown to display some of the same cell markers as oval cells 
(35, 36), it is not unreasonable to hypothesize that progenitor cells of marrow origin could act 
as a source of oval cells in the liver.  Further research needs to be done to elucidate a possible 
link between these two cell populations. 
Our studies did show that, as in previous studies, murine bone marrow cells are able 
to engraft in the liver and become hepatocytes after sex-mismatched bone marrow transplant 
with or without subsequent liver damage.  We observed co-labeling of the Y chromosome 
and HNF-1 in the single nucleus of single hepatocyte cells.  
 In the past, recipient phenotype has been identified using immunohistochemical or 
immunofluorescent detection of cytoskeletal proteins such as cytokeratin or secreted proteins 
such as albumin.  Both of these techniques can lead to incorrect interpretation of cells since 
their labeling location is in the periphery of the cell where borders between two cells may not 
be readily apparent.  Our findings of hematopoietic cells closely adjacent to liver cells make 
it clear that when employing a co-labeling technique for identification of cells of both donor 
and recipient origin, it is essential to use markers located in the nucleus of the target cell.  
This approach reduces the chance of mistaking a marrow derived hepatic cell for a marrow-
derived blood cell closely adjacent to a non-marrow-derived hepatic cell.  Our studies show 
that HNF-1 is an appropriate nuclear marker for recipient phenotype in this model.  Due to 
the specificity and location of HNF-1 labeling, it proves to be a reliable nuclear marker of 
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liver hepatocyte and cholangiocyte phenotype.  In addition, immunofluorescent localization 
of HNF-1 is compatible with Y-FISH in paraffin sections. 
Our use of Y chromosome detection by FISH was also a good choice for its 
specificity for donor phenotype and for its nuclear labeling location.  This is a more reliable 
technique than previously employed methods because it is not subject to the potential 
unreliability of reporter transgene expression, as can occur with LacZ or green fluorescent 
protein (GFP).  One pitfall to the use of the Y chromosome in paraffin sections, though, is 
that the Y chromosome takes up only a small portion of the nucleus, while the hepatocyte 
nucleus itself is relatively large.  Therefore since we are examining the tissue in one plane of 
section only, there is a chance that we are not in the same plane of section that the Y 
chromosome is in, and as a result we may underestimate the number of marrow-derived 
hepatocytes in a given tissue. In male controls, approximately 80% of hepatocytes are Y-
positive when using FISH labeling on 3 micrometer sections, so the magnitude of the false 
negative error is on the order of 20%.  
Further analysis of our specimens via three-dimensional imaging with confocal 
microscopy allowed us to unequivocally ensure that the Y chromosome and HNF-1 labeling 
were indeed in the same nucleus and not merely artifact arising from overlap of a blood cell 
above or below a hepatocyte.   
Even with the use of nuclear labels and confocal microscopy, the possibility of a 
single nucleated cell as the result of nuclear as well as cytoplasmic fusion still remains a 
possibility.   In the highly fusogenic environment of an inflammatory reaction, it is likely that 
fusion indeed occurs between donor-derived inflammatory cells and recipient hepatocytes.  
Inflammation is induced both in injury studies as well as in studies that do not intentionally 
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create specific injury, as the whole body irradiation required for obliteration of the recipients 
own bone marrow will create some degree of inflammation.  Our study was not specifically 
designed to detect fusion events, and the rarity of marrow-derived hepatocytes in this model 
limits its utility in addressing the fusion issue.  The phenomena of fusion and plasticity are 
not mutually exclusive.  To unequivocally distinguish marrow-derived hepatic cells arising 
from differentiation versus cell-cell fusion, a different model, such as the FAH mouse model 
of tyrosinemia, would be required (65, 81).  Since fusion, inflammatory cell infiltration, and 
location of labeling in the cell can all affect the counting of putative marrow-derived 
hepatocytes, these factors are likely a significant cause of discrepancy in various authors’ 
quantitative reports on the frequency with which marrow-derived hepatocytes are found.   
We employed an injury model to inhibit intrahepatic progenitors including oval cells 
and hepatocytes, and therefore encourage the conversion of marrow-derived cells into hepatic 
cells.  We found marrow-derived hepatocytes both in animals receiving damage, but also in 
control animals receiving no post-myeloablative damage.  In addition, we did not find a 
difference between animals receiving DDC and animals receiving DDC plus liver-specific 
irradiation.  While these results would imply that damage does not play a role in the 
phenomenon of bone marrow to hepatocyte conversion, this is not a conclusion that can be 
definitively drawn from this work since there were a very low number of marrow-derived 
hepatocytes found overall. 
While many questions remain to be answered when it comes to the hematopoietic 
stem cell and its potential for plasticity, the approach of using adult stem cells in cellular 
therapy, regeneration medicine, and in the treatment of tissue injury or disease remains an 
attractive one in many ways.  The moral and ethical barriers that limit use of human 
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embryonic stem cell experimentation and use are much less of a concern with adult stem 
cells.  Their easy accessibility in the circulation and bone marrow make hematopoietic stem 
cells attractive for use.  Harvesting of these cells for use in therapies would be relatively easy 
and minimally invasive, and therefore not limited by the shortage problems encountered with 
organ transplantation.  One can imagine a strategy in which bone marrow could be extracted 
from a patient, modified, and given back as autologous cell/gene therapy for the treatment of 
many diseases.   
While adult stem cells show potential promise for clinical use in hepatology, much 
more must be understood about these cells before they can be translated into clinical use.  We 
need to better understand the driving forces behind engraftment of marrow-derived hepatic 
cells, specifically, their role in both physiological maintenance and in liver injury.  
Understanding the mechanism of transdifferentiation or fusion events could allow us to 
deliver corrective genes in cell therapy and regenerative medicine.  In the liver, it is also 
becoming clear that marrow-derived cells directly influence the deposition of fibrotic matrix 
proteins by stellate cells, independent of either fusion or transdifferentiation.  Thus, it will be 
critical to define the role of marrow-derived cells in the progression from inflammation to 
fibrosis and cirrhosis in order to identify potential targets for therapeutic intervention. 
The adult stem cell is potentially a powerful source of clinically useful treatment for 
various diseases.  Improvement of our understanding of these cells may revolutionize how 
we treat tissue injury and disease.  All medical disciplines stand to benefit greatly from the 
potential uses of these cells. 
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Figure 1.  a. A flowchart of the experiment design.  b. Liver specific irradiation apparatus.  The radiation source 
was placed in the ring at the top.  The mouse was anesthetized and placed in a holding box.  A lead shield 
limited irradiation to the upper abdomen.  
43
a: Normal    b: Control   c: 0 weeks, - irradiation d: 0 weeks, + irradiation 
 
 
e:            1 week              2 weeks            3 weeks 
- irr:    
+ irr:    
 
                  6 weeks                9 weeks             12 weeks 
- irr:    
+irr:    
 
Fig 2: Hematoxylin and Eosin staining of murine liver sections. a: Normal.  b: Control group which received 
bone marrow transplant without liver specific irradiation or DDC.  No apparent abnormalities are seen in a or b.  
Note the presence of multi-nucleated cells in normal liver (arrow in 2.a.). c: Liver at 0 weeks after DDC 
treatment without liver specific irradiation.  d: Liver 0 weeks after DDC treatment in addition to liver specific 
irradiation.   e: Comparison of liver sections from animals without liver specific irradiation (- irr) and animals 
with liver-specific irradiation (+ irr) at different time points after completion of DDC diet (1, 2, 3, 6, 9, 12 



















































Figure 3.  DDC-induced biochemical injury is reversible and unaffected by hepatic irradiation with 1000 rads.  









































a                   b 
          
 
c       d 
 
Figure 4.  FISH and Immunofluorescence co-localization of Y chromosome and HNF-1 in liver.  Y 
chromosome is pink, HNF-1 is green.  Nuclear DNA is stained blue.  Autofluorescence of the hepatocyte 
cytoplasm is green-yellow.  Red blood cell autofluorescence appears bright yellow.  Both the Y chromosome 
and HNF-1 labeling are found in the nucleus.  Figure 4a shows normal male liver.  Most hepatocytes contain at 
least one Y chromosome.  Hepatocytes and cholangiocytes express HNF-1.  Figure 4b shows the complete 
absence of Y chromosome staining in normal female liver.  Nuclear labeling of HNF-1 is identical to that of the 
male liver.  Figure 4c shows a marrow-derived hepatocyte in a mouse from the experimental group receiving no 
liver-specific irradiation.  This animal was sacrificed 1 week post DDC insult.  Figure 4d is an enlarged version 
of the 4c.  It shows clearly the nucleus co-stained for Y-chromosome and HNF-1 as well as the hepatocyte 












a      b 
 
 
Figure 5.  Confocal microscopy of Y and HNF-1 co-labelled hepatocyte.  With confocal microscopy, the co-
labeling is confirmed to be contained within the same nucleus without any other cells intruding on this space.  
Y-chromosome is pink, HNF-1 is green.  Nuclear DNA is stained blue.  Figure 5a shows each labeling 
separately, and in the lower right, the total overlay.  Figure 5b shows the y-chromosome and HNF-1 labeling in 


















Table 1:  Y-Positive, HNF-1 Positive, Liver cells 
 
 Number Y-positive, HNF-1 
positive cells counted : 
Weeks after DDC 
recovery: 
Total HNF-1 positive cells 
counted: 
Control: 1 N/A   5,100 
    
Subtotal: 1    5,100 
 
 
   
Experimental:   37,500 
     - 
irradiation 
1   1 week  
     -  
irradiation 
1   9 weeks  
     -  
irradiation 
1 12 weeks  
     + 
irradiation 
1 12 weeks  
    
Subtototal:  4  37,500 
 
 
   






      
 
   
 
Figure 6.  Pitfalls in the search for a marrow-derived hepatocyte. Y-chromosome is pink, HNF-1 is green.  
Nuclear DNA is stained blue.  A potential marrow-derived hepatocyte is circled in white.  The cell resembles a 
binucleate hepatocyte, one nucleus (white arrow) is not HNF-1 positive. 
  
 
 
 
